-1753360571959.webp&w=3840&q=75)
2025 NOSCM | Immunotherapy in First Line Metastatic Setting
Overview
Dr. Eric Singhi reviewed immunotherapy in first-line metastatic settings, noting 30% five-year survival for PDL1 high patients.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Eric K. Singhi, MD
Date of Release
July 24th, 2025
Related Material
-1769183671548.webp&w=3840&q=75)
2026 MCM | Dealing with Long Term Effects of Breast Cancer Immunotherapy and Targeted Therapy
Immunotherapy
1 Chapter
Non-CME Credit Course
-1769183559393.webp&w=3840&q=75)
2026 MCM | Integrative Medicine and Cancer: How to Improve the Quality of Life and Well Being of Our Patients and Survivors
Immunotherapy
1 Chapter
Non-CME Credit Course